Metabolic dysfunction–associated steatotic liver disease
Metabolic dysfunction–associated steatotic liver disease (MAFLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a type of liver disease characterized by the accumulation of fat in the liver of people who drink little to no alcohol. It is closely associated with metabolic syndrome, which is why the name was changed to reflect its metabolic dysfunction origin.
Definition[edit | edit source]
MAFLD is defined by the presence of steatosis in patients who have overweight or obesity, type 2 diabetes mellitus, or evidence of metabolic dysregulation. The term MAFLD can be applied to both non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).
Epidemiology[edit | edit source]
MAFLD is the most common liver disorder in Western countries, affecting about 25% of the population. It is also increasingly recognized in developing countries due to the global epidemic of obesity and type 2 diabetes.
Pathophysiology[edit | edit source]
The pathogenesis of MAFLD is complex and involves multiple parallel hits, including insulin resistance, secretion of pro-inflammatory cytokines, oxidative stress, and mitochondrial dysfunction. The disease progresses from simple steatosis to steatohepatitis, fibrosis, and eventually cirrhosis and hepatocellular carcinoma.
Diagnosis[edit | edit source]
Diagnosis of MAFLD is usually made by imaging studies such as ultrasound, CT scan, or MRI, which can detect fat in the liver. Liver biopsy is the gold standard for diagnosing MAFLD, but it is invasive and has potential complications.
Treatment[edit | edit source]
The mainstay of treatment for MAFLD is lifestyle modification, including diet, exercise, and weight loss. Pharmacological therapies are also available, but their long-term efficacy and safety are still under investigation.
Prognosis[edit | edit source]
The prognosis of MAFLD varies depending on the stage of the disease. Patients with simple steatosis have a relatively benign course, while those with NASH, fibrosis, or cirrhosis have a higher risk of liver-related morbidity and mortality.
See also[edit | edit source]
| Metabolic dysfunction–associated steatotic liver disease Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
